BCTX

8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share. All of the common shares in the offering were offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, were approximately $4.7 million. The Company relied upon the exemption set forth in Section

424B5 - BriaCell Therapeutics Corp. (0001610820) (Filer)

Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3TWiST analysis, which measures time without disease symptoms or significant treatment-related toxicity, showed clinically meaningful benefit in heavily pre-treated MBC patients in the ongoing Phase 3 studyBiomarker analyses from the ongoing Phase 3 study further validates potential predictors of anti-cancer response initially reported in Phase 2 study 2026 ASCO Annual Meeting, May 29-June 2, 2026, at McCormick Place, Chicago, Illinois PHILADELPHIA and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWI

PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, are expected to be approximately $4.7 million. The offering is expected to close on

Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorSixth consecutive positive DSMB recommendation to proceed highlights the favorable safety and tolerability of BriaCell's novel immunotherapy approach Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies t

Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer (MBC) patientsBiomarker analyses from the ongoing Phase 3 study confirm predictors of anti-cancer response seen in Phase 2 PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce positive clinical data from three clinical data poster presentations and t

BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S. PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care,

Bria-PROS+ is BriaCell's next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating components of Bria-PROS+ enhance anti-tumor responsesBriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in prostate cancer in the coming months PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed manufacturing clinical supplies of Bria-PROS+, its next generatio

Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of Penn Medicine's Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell's ongoing pivotal Phase 3 clinical study (Bri

Over 315 patients screened and over 230 patients enrolled in BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer Enrollment momentum continues with strong clinical site and patient interestInterim topline data expected in 2026Positive interim overall survival results could support potential approval of Bria-IMT in metastatic breast cancerBriaCell's Bria-IMT combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company d

PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of NYU Langone Health's Laura and Isaac Perlmutter Cancer Center, a renowned cancer center in New York City, as a clinical trial site in its ongoing pivotal Phase 3 clinical study (Bria-ABC). BriaCell has enjoyed a marked uptick in interest from premier cancer centers and patient enrollment numbers following the prominent independent feature of its Phase 3 clinical trial in Nature Medicine's

FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy BriaCell has prepared clinical supplies of Bria-BRES+ and plans to initiate a Phase 1/2a clinical study in metastatic breast cancer in the coming months PHILADELPHIA and VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company develo

Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presentedBiomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The details of the poster presentation sessions and

Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line modelsImmune cells activated by Bria-OTS+ exhibit serial killing activity across multiple rounds of tumor cell challenge PHILADELPHIA and VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting positive data from its preclinical Bria-OTS+ platform at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17–22 at the Sa

Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of potential prognostic biomarkers upon further analyses of Phase 2 Bria-IMT™ study dataBria-OTS+™ in Preclinical Cancer Models to be presented on Tuesday April 21 from 2:00- 5:00 PM PST; Poster Number: 6701 PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it is

8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), today announced the completion of the previously announced asset purchase transaction (the "Transaction") pursuant to a definitive purchase agreement dated February 4, 2026 (the "Purchase Agreement"), under which BriaPro acquired BriaCell's exclusive license to develop and commercialize Soluble CD80 ("sCD80") as a biologic agent for the treatment of c

PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present four posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), two posters highlighting

10-Q - BriaCell Therapeutics Corp. (0001610820) (Filer)

PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA. The accepted abstracts highlight research related to BriaCell's cellular immunotherapy platform, including the Company's ongoing pivotal Phase 3 study of Bria-IMTᵀᴹ   in combination with an

8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL), BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2025 held on March 5, 2026 (the "Meeting"). A total of 48.31% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, co

25-NSE - BriaCell Therapeutics Corp. (0001610820) (Subject)

8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)